Clinical Trial Update: A Phase 1b/2 Study of MEDI4736 With Tremelimumab, MEDI4736 or Tremelimumab Monotherapy in Gastric or GEJ Adenocarcinoma [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1b/2 trial evaluating MEDI4736 (durvalumab) with tremelimumab, MEDI4736 alone, or tremelimumab alone in gastric or gastroesophageal junction adenocarcin…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Cancer
• Gastroesophageal Junction Cancer

Drugs mentioned

• MEDI4736 (Durvalumab)
• Tremelimumab (tremelimumab)

Snippet

Sponsor: MedImmune LLC | Conditions: Gastric or Gastroesophageal Junction Adenocarcinoma | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2020-05-11